ENTX - Entera Bio Ltd logo

Entera Bio Ltd

ENTX

Entera Bio Ltd develops oral peptide and protein replacement therapies, focusing on osteoporosis and related conditions. Its candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, utilizing the N-Tabβ„’ oral delivery platform.

βš•οΈ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago β†’$667today

Score Overview

1 Year
Score
Net Growth53.08%
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth-100.00%
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Score3.7
Net Growth55.96%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth-100.00%
Rev Trend20%
Revenue Consistencyβ€”
All Time
Score
Net Growth47.91%
Net Trend38%
Net Income Consistency
Rev Growth-100.00%
Rev Trend38%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Entera Bio Ltd has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ENTX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-21
$ 3.05β€”
1 Year2025-10-21
$ 2.3927.62%
5 Years2021-10-21
$ 4.57-33.26%
All Time2018-06-28
$ 6.28-51.43%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 5M$ 4M
2025$ 42K-$ 11M$ 7M
2024$ 181K-$ 9M$ 8M
2023$ 14K-$ 8M$ 11M
2022$ 134K-$ 13M$ 12M
2021$ 571K-$ 12M$ 24M
2020$ 365K-$ 9M$ 8M
2019$ 236K-$ 10M$ 15M
IPO2018$ 500K-$ 10M$ 11M
ENTX - Entera Bio Ltd logo

Entera Bio Ltd fundamental performance

Between 2020 and 2025, revenue declined from $ 365K to $ 42K and net income went from -$ 9M to -$ 11M. Revenue increased in 1 of those 5 years; net income in 2.

Entera Bio Ltd currently holds a 5-year HDB Score of 3.7 out of 10. How the HDB Score is calculated.

Membership

Explore ENTX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,118 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies